Besides, the development of radiopharmaceutical therapy for prostate cancer base on the labeled antibodies such as 225Ac-PSMA-617, 177Lu/225Ac-J591, 255Ac/90Y-hu5A10, 177Lu-SC16, 225Ac-YS5 for preclinical application on prostate cancer were evaluated17, but it is not currently available in Vietnam because imports are expensive. This evidence concerns the gene FOLH1 and Familial prostate cancer.